SEC Company Response from SOLIGENIX, INC. (SNGX) (CIK 0000812796) (SNGX) — Apr 2, 2008
SOLIGENIX, INC. (SNGX) (CIK 0000812796)
Date: April 2, 2008 · CIK: 0000812796 · Accession: 0000812796-08-000015
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-149239
Letter
s1accelerationfusion.htm
DOR BioPharma, Inc. 850 Bear Tavern Road, Suite 201, Ewing, New Jersey 08628
April 2,
Via EDGAR and Facsimile (202) 772-9217
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-4561
Attn: Jeffrey P. Riedler
Re: DOR BioPharma, Inc.
Registration Statement on Form S-1 (the "Registration Statement")
Initially Filed February 14,
File No. 333-149239
Ladies and Gentlemen:
The undersigned hereby respectfully requests, pursuant to Rule 461 of the Securities Act of 1933, as amended, that the Registration Statement on Form S-1 originally filed by DOR BioPharma, Inc. (the “Company”) with the United States Securities and Exchange Commission (the “Commission”) on February 14, 2008 (File No. 333-149239), as amended, be declared effective as of 4:00 p.m., Eastern Time, on Friday, April 4, 2008, or as soon thereafter as possible.
The undersigned hereby acknowledges that (i) should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; (ii) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and (iii) the Company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very
truly yours,
DOR
BioPharma, Inc.
Show Raw Text
CORRESP
1
filename1.htm
s1accelerationfusion.htm
DOR BioPharma, Inc. 850 Bear
Tavern Road, Suite 201, Ewing, New Jersey 08628
April 2,
2008
Via EDGAR and Facsimile
(202) 772-9217
United
States Securities and Exchange Commission
Division
of Corporation Finance
100 F
Street, N.E.
Washington,
D.C. 20549-4561
Attn: Jeffrey
P. Riedler
Re: DOR
BioPharma, Inc.
Registration Statement on Form S-1 (the
"Registration Statement")
Initially Filed February 14,
2008
File No. 333-149239
Ladies
and Gentlemen:
The
undersigned hereby respectfully requests, pursuant to Rule 461 of the Securities
Act of 1933, as amended, that the Registration Statement on Form S-1 originally
filed by DOR BioPharma, Inc. (the “Company”) with the United States Securities
and Exchange Commission (the “Commission”) on February 14, 2008 (File No.
333-149239), as amended, be declared effective as of 4:00 p.m., Eastern Time, on
Friday, April 4, 2008, or as soon thereafter as possible.
The
undersigned hereby acknowledges that (i) should the Commission or the staff,
acting pursuant to delegated authority, declare the filing effective, it does
not foreclose the Commission from taking any action with respect to the filing;
(ii) the action of the Commission or the staff, acting pursuant to delegated
authority, in declaring the filing effective, does not relieve the Company from
its full responsibility for the adequacy and accuracy of the disclosure in the
filing; and (iii) the Company may not assert the declaration of effectiveness as
a defense in any proceeding initiated by the Commission or any person under the
federal securities laws of the United States.
Very
truly yours,
DOR
BioPharma, Inc.
By: /s/ Christopher J,
Schaber
Christopher
J. Schaber
President
and Chief Executive Officer
cc: Leslie
J. Croland, Esq.